日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

乐伐替尼联合经动脉化疗栓塞术和PD-1抑制剂作为不可切除的中晚期肝细胞癌转化疗法:一项II期临床试验和探索性生物分子研究

Zhang, Xiaoyun; Cai, Haozheng; Peng, Wei; Wang, Haiqing; Wu, JiaYi; Zhu, Xinrui; Guo, Weixin; Xie, Fei; Zhang, Yu; Wang, Ming; Yu, Yu; Zhou, Yongjie; Li, Chuan; Shen, Junyi; Liu, Chang; Yang, Yu; Jiang, Xiaozhong; Li, Qiu; Chen, Weixia; Shi, Yujun; Lu, Wusheng; Sun, Xin; Feng, Xielin; Yan, Maolin; Cheng, Shuqun; Wen, Tianfu

Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study

在不可切除的肝细胞癌中,与单独使用立体定向放射治疗(SBRT)相比,SBRT联合PD-1抑制剂可提高疗效并延长长期生存期:一项多中心倾向性评分匹配研究

Wei, Xubiao; Jiang, Yabo; Li, Yong; Shi, Hong; Guo, Weixing; Shi, Jie; Zeng, Zhaochong; Wen, Tianfu; Jiao, Yang; Wang, Miaomiao; Cheng, Shuqun

Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)

中国肝细胞癌全程管理专家共识(2023版)

Yang, Yu; Sun, Juxian; Cai, Jianqiang; Chen, Minshan; Dai, Chaoliu; Wen, Tianfu; Xia, Jinglin; Ying, Mingang; Zhang, Zhiwei; Zhang, Xuewen; Fang, Chihua; Shen, Feng; An, Ping; Cai, Qingxian; Cao, Jingyu; Zeng, Zhen; Chen, Gang; Chen, Juan; Chen, Ping; Chen, Yongshun; Shan, Yunfeng; Dang, Shuangsuo; Guo, Wei-Xing; He, Jiefeng; Hu, Heping; Huang, Bin; Jia, Weidong; Jiang, Kexiang; Jin, Yan; Jin, Yongdong; Jin, Yun; Li, Gong; Liang, Yun; Liu, Enyu; Liu, Hao; Peng, Wei; Peng, Zhenwei; Peng, Zhiyi; Qian, Yeben; Ren, Wanhua; Shi, Jie; Song, Yusheng; Tao, Min; Tie, Jun; Wan, Xueying; Wang, Bin; Wang, Jin; Wang, Kai; Wang, Kang; Wang, Xin; Wei, Wenjing; Wu, Fei-Xiang; Xiang, Bangde; Xie, Lin; Xu, Jianming; Yan, Mao-Lin; Ye, Yufu; Yue, Jinbo; Zhang, Xiaoxun; Zhang, Yu; Zhang, Aibin; Zhao, Haitao; Zhao, Weifeng; Zheng, Xin; Zhou, Hongkun; Zhou, Huabang; Zhou, Jun; Zhou, Xinmin; Cheng, Shu-Qun; Li, Qiu

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

中国肝癌诊疗指南(2024版)

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Zhang, Bixiang; Tao, Kaishan; Han, Guohong; Yan, Zhiping; Wang, Maoqiang; Liu, Ruibao; Guo, Jinhe; Zeng, Zhaochong; Liang, Ping; Ren, Zhenggang; Hou, Jinlin; Zhang, Yanqiao; Liu, Xiufeng; Pan, Hongming; Bi, Feng; Liang, Changhong; Chen, Min; Yan, Fuhua; Xu, Huixiong; Xie, Xiaoyan; Ju, Shenghong; Ji, Yuan; Yun, Jingping; Li, Zengshan; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yajin; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Zhi; Dai, Chaoliu; Gao, Qiang; Guo, Rongping; Guo, Wengzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jiang, Hanyu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xiangcheng; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Liang, Xiao; Ling, Changquan; Liu, Hui; Liu, Tianshu; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Guoming; Shi, Hongcheng; Shi, Ming; Song, Tianqiang; Tan, Guang; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xia, Jun; Xing, Baocai; Xu, Jianming; Xu, Jun; Yang, Jianyong; Yang, Xinrong; Yang, Yefa; Yang, Yunke; Yao, Xiaohong; Yin, Zhenyu; Yuan, Zhengang; Zeng, Yongyi; Zeng, Yong; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Zhiwei; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Shi, Yinghong; Liu, Rong; Zhang, Lan; Xiao, Yongsheng; Yang, Chun; Wu, Zhifeng; Ding, Zhengbin; Zhu, Xiaodong; Tang, Zheng; Huang, Xiaoyong; Han, Hong; Wu, Hong; Chen, Minshan; Wang, Weilin; Li, Qiang; Cai, Jianqiang; Shen, Feng; Cai, Xiujun; Qin, Shukui; Teng, Gaojun; Fan, Jia

Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study

中晚期肝细胞癌患者的转化切除术或直接切除术:一项多中心研究

Zhou, Ying; Wang, Haiqing; Wu, Jiayi; Shen, Junyi; Ma, Ji; Li, Qiu; Chen, Weixia; Lu, Wusheng; Feng, Xielin; Yan, Maolin; Wen, Tianfu; Zhang, Xiaoyun

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

比较乐伐替尼与贝伐单抗联合免疫检查点抑制剂和介入三联疗法治疗中国晚期肝细胞癌的疗效:CLEAP 2302 研究

Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei

Prognostic assessment of early-stage liver cirrhosis induced by HCV using an integrated model of CX3CR1-associated immune infiltration genes

利用CX3CR1相关免疫浸润基因的整合模型对HCV诱导的早期肝硬化进行预后评估

Cai, Haozheng; Zhang, Jing; Chen, Chuwen; Shen, Junyi; Zhang, Xiaoyun; Peng, Wei; Li, Chuan; Lv, Haopeng; Wen, Tianfu

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study

根治性肝切除术后高危CNLC IIb/IIIa期肝细胞癌辅助治疗:一项前瞻性探索性研究

Sun, Hui-Chuan; Huang, Zhi-Yong; Wen, Tianfu; Liu, Lianxin; Zhu, Xiao-Dong; Zhang, Erlei; Li, Chuan; Zhang, Xiaoyun; Wang, Jiabei; Fan, Jia; Zhou, Jian

Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels

替诺福韦与恩替卡韦对乙型肝炎病毒相关肝细胞癌肝切除术后患者预后的影响:HBsAg水平的作用

Qiu, Zhancheng; Xu, Yueqing; Qi, Weili; Shen, Junyi; Wen, Tianfu; Li, Chuan

PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma

PERI-START:一项针对早期肝细胞癌的围手术期TACE、替雷利珠单抗和乐伐替尼治疗的II期临床试验

Kong, Diao; Tang, Yongcheng; Zhou, Yongjie; Zhou, Jin; Li, Chuan; Wen, Tianfu; Peng, Wei